Adage Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

Adage Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12M	Sell	2,664,941 -1,675,000	-39%	-$7.32M	0.02%	645
2025 Q4	$20.9M	Sell	4,339,941 -675,000	-13%	-$3.04M	0.03%	469
2025 Q3	$22.8M	Buy	5,014,941 +2,439,000	+95%	+$8.96M	0.04%	425
2025 Q2	$7.96M	Buy	2,575,941 +1,000,000	+63%	+$3.32M	0.01%	654
2025 Q1	$5.5M	Sell	1,575,941 -75,000	-5%	-$250K	0.01%	685
2024 Q4	$5.4M	Sell	1,650,941 -1,250,000	-43%	-$4.6M	0.01%	710
2024 Q3	$11.2M	Sell	2,900,941 -99,059	-3%	-$380K	0.02%	586
2024 Q2	$9.27M	Hold	3,000,000	–	–	0.02%	618
2024 Q1	$7.74M	Buy	+3,000,000	New	+$7.77M	0.01%	643

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Adage Capital Partners's ABUS Position: Q1 2026 in Review

Adage Capital Partners reduced its Arbutus Biopharma (ABUS) stake by 39% in Q1 2026, selling an estimated $7.32M and leaving 2,664,941 shares worth $12M. The position accounts for 0.02% of the portfolio, ranked #645.

Adage Capital Partners first reported a position in ABUS in Q1 2024 and has held it in 9 quarters since. The position peaked at $22.8M in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Adage Capital Partners held 2,664,941 shares of Arbutus Biopharma worth $12M as of Q1 2026.
Adage Capital Partners sold 1,675,000 Arbutus Biopharma shares in Q1 2026, an estimated $7.32M.
Arbutus Biopharma made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #645 holding.
Adage Capital Partners first reported a position in Arbutus Biopharma in Q1 2024 and has held it in 9 quarters since.
Adage Capital Partners's Arbutus Biopharma position peaked at $22.8M in Q3 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.